Compare ASYS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | ADAG |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.5M | 254.4M |
| IPO Year | 2006 | 2020 |
| Metric | ASYS | ADAG |
|---|---|---|
| Price | $16.66 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 210.2K | ★ 356.5K |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $1,677.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $1.44 |
| 52 Week High | $19.74 | $4.75 |
| Indicator | ASYS | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 42.78 |
| Support Level | $10.84 | $3.49 |
| Resistance Level | $18.00 | $3.53 |
| Average True Range (ATR) | 1.43 | 0.25 |
| MACD | 0.18 | -0.07 |
| Stochastic Oscillator | 55.37 | 15.71 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.